Advances and prospects of drug clinical research in colorectal cancer in 2022

Dan Su; Chao Liu; Jie Cui; Jiebing Tang; Yuli Ruan; Yanqiao Zhang

doi:10.1002/cai2.62

Advances and prospects of drug clinical research in colorectal cancer in 2022

Cancer Innov. 2023 Mar 5;2(2):99-113. doi: 10.1002/cai2.62. eCollection 2023 Apr.

Authors

Dan Su^{1

2}, Chao Liu^{1

2}, Jie Cui¹, Jiebing Tang^{1

2}, Yuli Ruan¹, Yanqiao Zhang^{1

2}

Affiliations

¹ Department of Gastrointestinal Medical Oncology Harbin Medical University Cancer Hospital Harbin Heilongjiang Province China.
² Clinical Research Center for Colorectal Cancer in Heilongjiang Harbin Medical University Cancer Hospital Harbin Heilongjiang Province China.

Abstract

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death worldwide. Clinical research results have provided more treatment opportunities for CRC patients, showing that an optimal combination of existing drugs and new drugs is needed to mitigate the burden of this disease. In this review, we have summarized recent advances in drug clinical research for CRC in 2022, including chemotherapy, targeted therapy, and immunotherapy, to find opportunities for substantial improvements in drug discovery and clinical development methods.

Keywords: chemotherapy; colorectal cancer; immunotherapy; targeted therapy.

Publication types

Review